Chao H. Huang

Peter J. Van Veldhuizen2
Nora J. Smart2
Stephen K. Williamson2
2Peter J. Van Veldhuizen
2Nora J. Smart
2Stephen K. Williamson
Learn More
  • Chao H. Huang, Jo A. Wick, Gurusingham Sitta Sittampalam, Victor Sanjit Nirmalanandhan, Apar Kishor Ganti, Prakash C. Neupane +6 others
  • 2014
BACKGROUND Small-cell lung cancer (SCLC), a variant of lung cancer marked by early metastases, accounts for 13% of all lung cancers diagnosed in US. Despite high response rates to treatment, it is an aggressive disease with a median survival of 9-11 months for patients with extensive stage (EX-SCLC). Detection of circulating tumor cells (CTCs) is a novel(More)
BACKGROUND A recent study reviewed phase III trials of first-line advanced non-small cell lung cancer (NSCLC) conducted from 1981 to 2010, and provided trends in the study outcome. However, such trials have never been analyzed in detail for design and stratification factors. METHODS Phase III studies of systemic treatment for first-line advanced or(More)
BACKGROUND Insulin-like growth factor 1 receptor (IGF-1R) regulates cell growth, proliferation, and apoptosis. Adenocarcinoma and never-smokers have a higher expression of IGF-1R, which is associated with worse overall survival. Dalotuzumab-MK0646 (D) is a humanized monoclonal antibody that targets IGF-1R. Pemetrexed (P) has higher activity in non-squamous(More)
The epidermal growth factor receptor (EGFR) plays an important role in the development of many cancers, including non-small cell lung cancer. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are a class of novel biologically-targeted agents widely used in the management of recurrent non-small cell lung cancer. Erlotinib, one of the(More)
  • 1